Corporate Banner
Satellite Banner
Technology
Networks
Scientific Communities
 
Become a Member | Sign in
Home>News>This Article
  News
Return

Alvetex® Voted One of Most Technologically Significant New Research Products By R&D Magazine

Published: Monday, June 27, 2011
Last Updated: Monday, June 27, 2011
Bookmark and Share
Alvetex® enables genuine 3D cell growth to be performed routinely and cost effectively in cell biology laboratories.

Reinnervate, has announced that alvetex®, its breakthrough 3D cell culture technology, is among the winners of the prestigious 49th Annual R&D 100 Awards.

Alvetex® is a unique and proprietary cell culture scaffold that, for the first time, enables genuine 3D cell growth to be performed routinely and cost effectively in cell biology laboratories.

Reinnervate launched its first product, the alvetex® 12-well plate, in Europe at the end of November 2010 and introduced 6-well and 12-well inserts and petri dish formats at the end of March 2011.

The Company intends to launch alvetex® products in a range of other formats over the next 12 months, including 24, 48 and 96 well plates.

Alvetex was chosen by an independent judging panel and the editors of R&D Magazine to be among the 100 most technologically significant products introduced into the marketplace over the past year.

The award will be presented to reinnervate at a special Gala Awards Banquet at the Renaissance Orlando Hotel at SeaWorld in Florida on 13th October 2011.

“The editors were impressed with the strong field of candidates for this year’s R&D 100 Awards. The number and quality of entrants far exceeded that of recent years,” said Rita Peters, editorial director of R&D Magazine.

Professor Stefan Przyborski, reinnervate’s Chief Scientific Officer and founder, commented: “We are extremely proud that alvetex® has been selected as one of this year’s winners of the annual R&D 100 Awards. The team here at reinnervate and at Durham University have shown great dedication in bringing our game-changing alvetex® technology to market and this award goes some way towards recognizing their work. Here at reinnervate we continue to innovate and intend to launch further alvetex® products onto the market over the next 12 months, including a 96-well plate suitable for high-throughput drug screening.”

Since 1963, the R&D 100 Awards have identified revolutionary technologies newly introduced to the market, many of which have become household names.

Winners are picked from industry sectors as diverse as telecommunications, high-energy physics, software, manufacturing, and biotechnology and represent a cross-section of industry, academia, private research firms and government labs.


Further Information
Access to this exclusive content is for Technology Networks Premium members only.

Join Technology Networks Premium for free access to:

  • Exclusive articles
  • Presentations from international conferences
  • Over 2,500+ scientific posters on ePosters
  • More Than 3,800+ scientific videos on LabTube
  • 35 community eNewsletters


Sign In



Forgotten your details? Click Here
If you are not a member you can join here

*Please note: By logging into TechnologyNetworks.com you agree to accept the use of cookies. To find out more about the cookies we use and how to delete them, see our privacy policy.

Related Content

Reinnervate Partners with Oncotest and SBH Sciences
Companies to partner on introductory services for screening novel anti-cancer drugs using 3D tumour cell culture.
Thursday, October 31, 2013
Reinnervate Ltd and Roslin Cellab Partner
Reinnervate Ltd announced that it is entering into a collaboration with Roslin Cellab to develop 3D stem cell printing products and services using Alvetex® technology.
Friday, September 20, 2013
3D cell Culture Firm Reinnervate and Specialist Oncology CRO Oncotest GmbH Enter Collaboration Agreement
Oncotest to offer enhanced pre-clinical oncology and cancer research screening services incorporating Alvetex®Scaffold 3D cell culture technology.
Monday, January 07, 2013
Reinnervate and Tecan Sign Co-marketing Agreement
Both Companies to develop automated 3D cell culture solutions for improved cellular assays.
Tuesday, November 27, 2012
Reinnervate and Roslin Cellab Announce Plans to Collaborate
Collaboration on the development of protocols for three dimensional growth of hESC’s using Alvetex®Scaffold.
Friday, April 27, 2012
Reinnervate and Kirkstall to Collaborate on New 3D Cell Culture Products
Companies will collaborate to bring next generation three dimensional (3D) cell culture products to market in 2012. The two UK companies develop cell culture systems that bridge the current gap between 2D in-vitro cell culture and animal models.
Monday, March 19, 2012
New Reinnervate Whitepaper Includes Details on Live 3D Cell Imaging in 3D Cell Culture Using Alvetex®
The release is set to help scientists make the switch from traditional 2D cell culture to 3D cell growth.
Monday, January 30, 2012
Reinnervate and Mirus Bio announce collaboration
Reinnervate and Mirus Bio announce commercial agreement to launch new range of products for the transfection of cells cultured in 3D.
Friday, November 18, 2011
Reinnervate Partners with AMS Biotechnology (Europe) Limited for Distribution of Alvetex®
Alvetex® is a unique and proprietary cell culture scaffold that enables genuine 3D cell growth to be performed routinely and cost-effectively in cell biology laboratories.
Wednesday, June 01, 2011
Reinnervate Enhances Commercial and Product Development Teams with Key Senior Appointments
Appointments of Richard Rowling as commercial director and Barry Lynch as marketing manager to lead the sales and marketing operations supporting alvetex®.
Wednesday, April 06, 2011
Alvetex® Named in the “Top Ten Life Science Innovations of 2010” by The Scientist Magazine
Reinnervate’s 3D cell culture technology selected as one the ten most exciting new tools to hit the life sciences market this year.
Monday, December 06, 2010
Reinnervate Partners with LGC for Global Distribution of Alvetex®
Additional collaboration to develop 3d cell cultures for applications in drug discovery and development.
Tuesday, November 30, 2010
Reinnervate Partners with LGC for Global Distribution of ALVETEX®
Additional collaboration to develop 3D cell cultures for applications in drug discovery and development.
Monday, November 29, 2010
Reinnervate Completes Expansion into New Purpose-Built Facility at Netpark
Reinnervate, a life sciences company driving the adoption of routine 3D cell culture, has announced its expansion into a new purpose-built research and production facility at NETPark near Sedgefield, UK.
Tuesday, November 16, 2010
Reinnervate Launches new Website with Interactive Technical Resource for Routine 3D Cell Culture
New site provides scientific and technical information on 3D cell culture based on Reinnervate’s core Alvetex® technology.
Wednesday, October 13, 2010
Scientific News
NIH Study Finds Calorie Restriction Lowers Some Risk Factors for Age-Related Diseases
Two-year trial did not produce expected metabolic changes, but influenced other life span markers.
Immunotherapy Agent Benefits Patients with Drug-Resistant Multiple Myeloma in First Human Trial
Daratumumab proved generally safe in patients, even at the highest doses.
Low-level Arsenic Exposure Before Birth Associated with Early Puberty in Female Mice
Study examine whether low-dose arsenic exposure could have similar health outcomes in humans.
Inciting an Immune Attack On Cancer Cells
A new minimally invasive vaccine that combines cancer cells and immune-enhancing factors could be used clinically to launch a destructive attack on tumors.
‘Mutation-Tracking’ Blood Test for Breast Cancer
Scientists have developed a blood test for breast cancer able to identify which patients will suffer a relapse after treatment, months before tumours are visible on hospital scans.
Cellular Contamination Pathway for Heavy Elements Identified
Berkeley Lab scientists find that an iron-binding protein can transport actinides into cells.
Intensity of Desert Storms May Affect Ocean Phytoplankton
MIT study finds phytoplankton are extremely sensitive to changing levels of desert dust.
Common ‘Heart Attack’ Blood Test May Predict Future Hypertension
Small rises in troponin levels may have value as markers for subclinical heart damage and high blood pressure.
LaVision BioTec Reports on the Neuro Research on the Human Brain After Trauma
Company reports on the work of Dr Ali Ertürk from the Institute for Stroke and Dementia Research at LMU Munich.
NIH Study Shows No Benefit of Omega-3 Supplements for Cognitive Decline
Research was published in the Journal of the American Medical Association.
Scroll Up
Scroll Down
Skyscraper Banner

Skyscraper Banner
Go to LabTube
Go to eposters
 
Access to the latest scientific news
Exclusive articles
Upload and share your posters on ePosters
Latest presentations and webinars
View a library of 1,800+ scientific and medical posters
2,500+ scientific and medical posters
A library of 2,500+ scientific videos on LabTube
3,800+ scientific videos
Close
Premium CrownJOIN TECHNOLOGY NETWORKS PREMIUM FREE!